Charles River Laboratories International, Inc. Stock
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
208.4 USD | -0.61% | -4.04% | -11.83% |
Financials (USD)
Sales 2024 * | 4.22B | Sales 2025 * | 4.53B | Capitalization | 10.74B |
---|---|---|---|---|---|
Net income 2024 * | 406M | Net income 2025 * | 513M | EV / Sales 2024 * | 3 x |
Net Debt 2024 * | 1.94B | Net Debt 2025 * | 1.46B | EV / Sales 2025 * | 2.69 x |
P/E ratio 2024 * |
26.4
x | P/E ratio 2025 * |
21.3
x | Employees | 21,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.94% |
Latest transcript on Charles River Laboratories International, Inc.
1 day | -0.61% | ||
1 week | -4.04% | ||
1 month | -8.98% | ||
3 months | -18.00% | ||
6 months | +5.76% | ||
Current year | -11.83% |
Managers | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 73 | 75-12-31 |
Flavia Pease
DFI | Director of Finance/CFO | 51 | 22-04-24 |
Birgit Girshick
COO | Chief Operating Officer | 54 | 89-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Massaro
BRD | Director/Board Member | 76 | 02-12-31 |
Virginia Wilson
BRD | Director/Board Member | 68 | 19-09-30 |
Robert Bertolini
BRD | Director/Board Member | 61 | 11-01-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.05% | 1 M€ | -.--% | - | |
2.07% | 5 M€ | -1.80% | - | |
1.08% | 0 M€ | 0.00% | - | |
0.98% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 208.4 | -0.61% | 762,316 |
24-05-30 | 209.7 | -0.83% | 469,115 |
24-05-29 | 211.5 | -1.41% | 362,887 |
24-05-28 | 214.5 | -1.24% | 534,356 |
24-05-24 | 217.2 | -0.16% | 312,749 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.83% | 10.74B | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- CRL Stock